The Therapeutic Effect of Catgut Embedding in Obesity

October 23, 2014 updated by: Chung-Hua Hsu, Taipei City Hospital

The Therapeutic Effect of Catgut Embedding in Obesity-A Randomized, Double-blind, Placebo-controlled Clinical Trial

The aim of this double-blind, randomized, placebo-controlled trial is to evaluate the therapeutic effects of acupoint stimulation by catgut embedding on complexion, quality of life, lipid profile, inflammatory markers, and obesity-related hormone peptide of obese women.

Study Overview

Detailed Description

We will recruit 90 females aged from 16 year-old to 65 year-old with body mass index(BMI) 27㎞/㎡ and waist circumference≧80cm. After inform consent, they will be randomly assigned into two groups. In group A, catgut embedding will be applied to six acupuncture points on the abdomen including Qihai (Ren-6), Shuifen (REN-9), bilateral shuidao (ST-28) and Siman (ST-26), which have been proved to be effective on obesity in our previous study, once each week for six times. In group B, sham catgut embedding will be applied on the same acupoints once each week for six weeks. This trial will go on for six weeks with six course of treatment.

Our primary outcome measurements is complexion which included body mass index(BMI),waist circumstances, and waist-hip ratio. In our second outcome measurments, we will evaluate the life quality of these patients using 12-Item Short Form Health Survey (SF-12) which developed for the Medical Outcomes Study (MOS) and also using questionnaire of quality of life that was designated by World Health Organization. We will also classify the patients by questionnaire designed for TCM syndrome of obesity. We will check blood test included lipid profile (TG, Chol, HDL-C, LDL-C), inflammatory markers, and hormone peptide related to obesity such as insulin,leptin,ghrelin,adiponectin. Each enrolling patients will be evaluated at the baseline before treatment and after 6 times treatments completed by above parameters to find out the therapeutic effects and mechanism of catgut embedding in acupoints in obese women.

Study Type

Interventional

Enrollment (Anticipated)

90

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Taipei, Taiwan, 886
        • Branch of Chinese Medicine, Taipei City Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 65 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • body mass index (BMI) ≥ 27 kg/m2 waist circumference (WC) ≥ 80 cm and willing to participate in and fill out the questionnaires for this trial.

Exclusion Criteria:

  • Endocrine disease(Thyroid disease, pituitary disease, diabetes mellitus) Autoimmune disease(SLE、SSS、RA) Heart disease(Heart failure, arrhythmia etc.) Abnormal liver function(GOT>80U/L、GPT>80U/L) Abnormal kidney function(serum creatinine>2.5 mg/dL) Stroke disease in past one year Under breast feeding or pregnancy Coagulation disorder Subjects with keloid disorder Accept weight reduction treatment in last two months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: QUADRUPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: catgut embedding group
Catgut will be embedding in acupoints as below. Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26) Frequency: one time per week Duration: 6 weeks

An extensive form of acupuncture that involves weekly infixing self-absorptive chromic catgut sutures into acupoints with a specialised needle under antiseptic precautions. The catgut then stimulate those points over a long period. The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger with chromic catgut in front of the syringe needle. Catgut will be embedding in acupoints as below.

Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)

Other Names:
  • acupoint catgut embedding
SHAM_COMPARATOR: sham catgut embedding group

The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger without chromic catgut in front of the syringe needle. All the procedure will be performed as in catgut embedding group.

Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)

The other procedure were the same as catgut embedding group Frequency: one time per week Duration: 6 weeks

The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger without chromic catgut in front of the syringe needle. Catgut will be embedding in acupoints as below.

Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)

Other Names:
  • sham acupoint catgut embedding

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
body weight
Time Frame: assessed at each time before procedures and one week after the 6th treatment, an expected average of 7 weeks
assessed at each time before procedures and one week after the 6th treatment, an expected average of 7 weeks
body mass index
Time Frame: assessed at each time before procedures and one week after the 6th treatment, an expected average of 7 weeks
assessed at each time before procedures and one week after the 6th treatment, an expected average of 7 weeks
waist circumference
Time Frame: assessed at each time before procedures and one week after the 6th treatment, an expected average of 7 weeks
assessed at each time before procedures and one week after the 6th treatment, an expected average of 7 weeks
hip circumference
Time Frame: assessed at each time before procedures and one week after the 6th treatment, an expected average of 7 weeks
assessed at each time before procedures and one week after the 6th treatment, an expected average of 7 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
cholesterol
Time Frame: Assess at baseline and after 6 weeks of treatment
cholesterol (Chol),
Assess at baseline and after 6 weeks of treatment
triglyceride (TG)
Time Frame: Assess at baseline and after 6 weeks of treatment
triglyceride (TG),
Assess at baseline and after 6 weeks of treatment
low-density lipoprotein cholesterol (LDL-C)
Time Frame: Assess at baseline and after 6 weeks of treatment
low-density lipoprotein cholesterol (LDL-C)
Assess at baseline and after 6 weeks of treatment
High-density lipoprotein cholesterol(HDL-C)
Time Frame: Assess at baseline and after 6 weeks of treatment
High-density lipoprotein cholesterol(HDL-C)
Assess at baseline and after 6 weeks of treatment
Quality of life
Time Frame: Assess at baseline and after 6 weeks of treatment
short-form 12 items and WHOQOLBREF
Assess at baseline and after 6 weeks of treatment
Questionnaire on traditional Chinese medicine syndrome groups
Time Frame: Assess at baseline and after 6 weeks of treatment
Obesity subjects will be classified into six groups including stomach heat, yin deficiency, qi stagnation, qi deficiency, kidney deficiency and blood stasis With more than two "yes"in items, patient will be classified to that kind of syndrome
Assess at baseline and after 6 weeks of treatment
sugar
Time Frame: Assess at baseline and after 6 weeks of treatment
AC sugar,
Assess at baseline and after 6 weeks of treatment
glycohemoglobin
Time Frame: Assess at baseline and after 6 weeks of treatment
glycohemoglobin (HbA1c),
Assess at baseline and after 6 weeks of treatment
liver function
Time Frame: Assess at baseline and after 6 weeks of treatment
ALT
Assess at baseline and after 6 weeks of treatment
kidney function
Time Frame: Assess at baseline and after 6 weeks of treatment
Cr
Assess at baseline and after 6 weeks of treatment
inflammatory markers
Time Frame: Assess at baseline and after 6 weeks of treatment
hsCRP
Assess at baseline and after 6 weeks of treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2014

Primary Completion (ANTICIPATED)

December 1, 2014

Study Completion (ANTICIPATED)

December 1, 2014

Study Registration Dates

First Submitted

October 14, 2014

First Submitted That Met QC Criteria

October 23, 2014

First Posted (ESTIMATE)

October 28, 2014

Study Record Updates

Last Update Posted (ESTIMATE)

October 28, 2014

Last Update Submitted That Met QC Criteria

October 23, 2014

Last Verified

October 1, 2014

More Information

Terms related to this study

Other Study ID Numbers

  • 101XDAA00024

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obese Women

Clinical Trials on Catgut embedding group

3
Subscribe